Icon

Safyral - (3mg,N/A; 0.03mg,N/A; 0.451mg,0.451mg, Tablet, Oral)

Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium Bayer
3mg,N/A; 0.03mg,N/A; 0.451mg,0.451mg, Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
Indicated in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.
Yes
****** ** *** ***** ** **** **** ** **** ******* **** ****** '*** (***** **, ****) *** *** ************ *********. ******** ***** ***** *** ****** ** ***** *** ********* ** ******. ****** ***** ***** **** ** **** **** ****** *** *** ************ *********. ****** ******** *** ******** ** ******* ******* ***** ******* ******* ******** *** ******** *****'* ******* ******* **** *** ****** '*** ** *******. ******* ***** ***** ** ****** ** ******* ***** ***** ******* ***** **** ******** ******* *******'* ********, ** ********* *** ****** ** *******. ***** *** ***** ***** ******* ********** *** **** ******** ***** '*** *** **** *** *** **** ** *** **********.
Safyral Patent 1 Patent 2 Patent 3 Patent 4
****** *** ********* *** ********* *** ********* *** ** **
***** *** ********* *** ********* *** ********* *** ** **
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** *, **** *** ** ** ******** *** ****** *** ****
***** ** \ ** *** **, **** *** ** ** ******** ******** ** *** *, ****
  1. *** **, **** : ****** ******** ***** ***** *** **** ** *** ******* **** ******* '*** (***** **, ****).
  2. *** **, **** : ***** ***** **** ******* ****** ** ******** ***** ** ******.
  3. *** **, **** : ***** ***** * **** ******* ***** ** ***** ***** **** ** **** ****** '*** (***** **, ****).
  4. *** *, **** : ********** *** ****** **** ***** **** *** ******* ** ******* ******* ** *** ****** ****.
  5. *** **, **** : ***** ***** ******* ****** ******* **** ****** '*** ** ***** *** ********* ** ******.
  6. *** **, **** : ****** ******** *** ******** ** ******* *******.
  7. *** **, **** : ******* ******* ******** ******** ***** ****** ******* **** '*** ****** ** *******.
  8. *** **, **** : ***** ******** *** ******** ** ******* *****.
  9. *** **, **** : * ********* ** ******* ** ***** ** ***** ****, '*** ****** ** *** ********* ** *****
  10. *** *, **** : ******* ***** ******** ******* *******'* ******** ** ********* *** ****** ** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.